Last reviewed · How we verify
Migliol Placebo Oil
Migliol is a medium-chain triglyceride oil used as a placebo or inert control vehicle in clinical trials.
Migliol is a medium-chain triglyceride oil used as a placebo or inert control vehicle in clinical trials. Used for Placebo control in clinical trials.
At a glance
| Generic name | Migliol Placebo Oil |
|---|---|
| Sponsor | Barts & The London NHS Trust |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Migliol (also known as Miglyol) is a pharmaceutical-grade medium-chain triglyceride (MCT) oil composed primarily of capric and caprylic acids. It is pharmacologically inert and is commonly used as a placebo comparator or vehicle in clinical studies rather than as an active therapeutic agent. In Phase 3 trials, it serves as a control to assess the efficacy of investigational drugs.
Approved indications
- Placebo control in clinical trials
Common side effects
Key clinical trials
- Vitamin D Effects in Overweight Patients (NA)
- Vitamin D and Mortality in Heart Failure (PHASE4)
- Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis (PHASE4)
- Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease (PHASE4)
- A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients (PHASE3)
- Trial of Adjunctive Vitamin D in Tuberculosis Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Migliol Placebo Oil CI brief — competitive landscape report
- Migliol Placebo Oil updates RSS · CI watch RSS
- Barts & The London NHS Trust portfolio CI